Supply agreement with Pharmabiota Ltd

RNS Number : 1577L

OptiBiotix Health PLC

17 July 2017

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

LP_LDL® supply agreement for New Zealand & Australia with Pharmabiota Ltd

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has agreed to develop and supply three different products containing LP_LDL®, with minimum initial purchase of 10,000 boxes of each, to Pharmabiota NZ Limited ("Pharmabiota").

Pharmabiota, based in New Zealand, was founded by pharmacist Peter Lagan to provide high quality and scientifically validated innovative products through its growing retail pharmacy partner network throughout New Zealand and Australia.

This agreement covers the initial development and supply of three products, packaged and released by Pharmabiota, containing LP_LDL® in different dosage forms and provides initial moderate levels of income, growing to six figure revenues in the second year, and a commitment of 10% annual growth. The deal reflects the growing industry awareness in LP_LDL® as a functional component in a wide range of consumer healthcare and pharmaceutical products worldwide.

This interest arises from OptiBiotix's innovative science, good clinical data & strong key opinion leader support, and the products ability to reduce both cholesterol and blood pressure. The agreement is the first step outside Europe in a business to business (B2B) strategy of bringing OptiBiotix's science together with a partner's national brand portfolio and market presence to serve multiple consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this agreement to develop and supply multiple consumer products containing LP_LDL® to Pharmabiota to be sold through its extensive antipodean partner network. We see this as another step in the Company's strategy of building multiple revenue streams from LP_LDL® ingredient supply (from our profit share with Sacco), and as a component in high value white label and branded formulations, across a range of national pharmacy and large consumer health international partners. This is a low risk, low cost approach, to accessing multiple consumer healthcare and pharmaceutical markets around the world. We are at the start of the commercialisation process but are really excited at the high level of interest in our products and the prospect of building multiple revenue streams, which if this strategy is successful, have the potential to cumulatively generate substantive seven figure revenues in the forthcoming years."

For further information. Please contact:

OptiBiotix Health plc		www.optibiotix.com
Stephen O'Hara, Chief Executive		Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)		Tel: [phone]
Liam Murray / Jo Turner
finnCap (Broker)		Tel: [phone]
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or                                 [e-mail]
Anna Dunphy		Mob: [phone]

About OptiBiotix - www.optibiotix.com 

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

END

 

 

AGRLLFISDIISLID